These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12324628)

  • 41. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
    Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topotecan in platinum-resistant epithelial ovarian cancer.
    Karabulut B; Sezgin C; Terek MC; Uslu R; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Goker E
    Chemotherapy; 2005 Oct; 51(6):347-51. PubMed ID: 16227688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current role and future aspects of topotecan in relapsed ovarian cancer.
    Sehouli J; Oskay-Ozcelik G
    Curr Med Res Opin; 2009 Mar; 25(3):639-51. PubMed ID: 19232038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
    Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
    Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ovarian cancer--therapeutic options after the failure of the first line of treatment].
    Jabłońska E; Chłosta M; Pawlega J
    Ginekol Pol; 2004 Jan; 75(1):58-64. PubMed ID: 15112475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
    Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
    J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.
    Balat O; Ugur MG
    Clin Exp Obstet Gynecol; 2003; 30(2-3):151-2. PubMed ID: 12854864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
    Li JD; Guan ZZ; Liu JH; Xin XY; Cui Y; Huang CJ; Liu FY; Song L; Bian ML; Zhou QH
    Ai Zheng; 2002 Apr; 21(4):416-20. PubMed ID: 12452024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
    Pectasides D; Psyrri A; Pectasides M; Economopoulos T
    Expert Opin Pharmacother; 2006 Jun; 7(8):975-87. PubMed ID: 16722809
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
    Tay SK; Thilagam MD
    Ann Acad Med Singap; 1998 Sep; 27(5):645-9. PubMed ID: 9919333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
    Gordon AN; Fleagle JT; Guthrie D; Parkin DE; Gore ME; Lacave AJ
    J Clin Oncol; 2001 Jul; 19(14):3312-22. PubMed ID: 11454878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of treatment-related toxicity in advanced ovarian cancer.
    Dunton CJ
    Oncologist; 2002; 7 Suppl 5():11-9. PubMed ID: 12324629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.